> ## Content Index > Fetch the complete content index at: https://www.moatmarginresearch.com/llms.txt > Use this file to discover other available public pages before exploring further. # Apollo Hospitals Enterprise Moat Analysis: Score & Risks - URL: https://www.moatmarginresearch.com/apollo-hospitals-enterprise-moat/ - Published: 2026-08-16T16:50:45.000Z - Updated: 2026-08-22T05:13:31.000Z - Author: A K Karthikeyan - Tags: First-pass note, Coverage Moat Note · First-pass ## Apollo Hospitals Enterprise Ltd. A first-pass moat teardown of Apollo Hospitals Enterprise Ltd., built from single-pass filing evidence. Free note — provisional, and the full two-pass deep dive may revise it. **Moat & Margin**16 Aug 2026 First-pass · \~3 min 4.90 / 10 NARROWProcess/Data-led First-pass narrow read — primary edge in Network Effects. Provisional, single-pass evidence. Provisional score · subject to modification based on new evidence Apollo Hospitals Enterprise Ltd. scores **4.9** on MoatSCORE 6.0 — a narrow moat in Pharma. This is a **first-pass note**: the dimensional read and the filing receipts below come from a single GFIP evidence pass, not the full two-pass deep corpus behind our flagship deep dives. Provisional — published free while the deep version is queued. The teardown ## Seven dimensions of moat Ordered by contribution. Each dimension carries a verified filing quote, graded **\[M\]** mechanism or **\[O\]** outcome. D1Network Effects5.7 M · Mechanism✓ Verified verbatim “Apollo Pharmacy, India's largest pharmacy network serves 600 cities and towns” **Apollo Hospitals Enterprise Ltd.** · FY2020 Annual Report · p.2 D2Switching Costs5.5 M · Mechanism✓ Verified verbatim “The term of the agreement shall be for a period of 10 years commencing from 1st September 2020.” **Apollo Hospitals Enterprise Ltd.** · FY2021 Annual Report · p.124 D3Cost Advantage4.8 O · Outcome✓ Verified verbatim “the company continues to derive a majority of its revenue from the Chennai cluster, followed by Hyderabad and Bengaluru. Tamil Nadu contributed 36% to the consolidated healthcare services revenue in FY23 (FY22: 34%)” **Apollo Hospitals Enterprise Ltd.** · Rating Rationale 1 quote extracted here — not one mechanism-class. The evidence is outcome-only. D4Price Discretion4.8 M · Mechanism✓ Verified verbatim “Building these COEs out as destination centres, will result in a better case mix and thereby a higher margin profile” **Apollo Hospitals Enterprise Ltd.** · FY2023 Annual Report · p.214 D5Intangible Assets4.8 M · Mechanism✓ Verified verbatim “of the losses in new hospitals will remain at INR 140 crore to INR 150 crore.” **Apollo Hospitals Enterprise Ltd.** · Earnings Call · p.12 D6Efficient Scale4.8 M · Mechanism✓ Verified verbatim “24/7 EBITDA losses were at Rs. 73 crore, significantly lower than Rs. 116 crore in Q1 FY25.” **Apollo Hospitals Enterprise Ltd.** · Earnings Call · p.2 D7Counter-PositioningExcluded— Excluded for this archetype. D8Ungoverned RiskUnscored · Layer 2.5 D8 rating: **ADEQUATE**. Not part of the moat score — it governs the cost of equity and the fade window. First-pass; not yet deep-reviewed. The barrier gate ## The barrier gate — first-pass Replication — can a rival copy it?5.0 How hard it is for a rival to copy the edge (first-pass estimate). Bypass — can a rival route around it?5.0 How easily a rival can route around the edge (first-pass estimate). Effective barrier 5 — below 6, so the band is capped narrow. First-pass estimate. What would change our mind 1. **Deep two-pass review.** This draft rests on a single GFIP evidence pass; the full 10-year AR + concall corpus may move the read. 2. **The barrier gate.** A firmer replication or bypass estimate is the most likely thing to shift the band. 3. **Adverse events.** Any governance, regulatory or funding shock captured in D8 could re-rate the fade window. First-pass note — provisional single-pass MoatSCORE 6.0 read, not the full deep dive. Educational research, not investment advice; no buy/sell recommendation, no price target. Moat & Margin is not a SEBI-registered Research Analyst or Investment Adviser. **Where this note fits.** This company is one of **509 Indian companies** we have scored for moat durability — 370 narrow, 126 narrow-trending-wide, none wide. Every score, dimension by dimension, is free in the [Moat Screener](https://www.moatmarginresearch.com/moat-screener/).